Insulet's next-gen insulin pump gains 510(k) clearance; Italian researchers eye wood as hip replacement material;

 @FierceMedDev: InVivo Therapeutics is seeing an HDE for its biopolymer scaffolding product. Clinical trial starts in early 2013. News | Follow @FierceMedDev

@MarkHFierce: Zoll says its "temperature management solution" device treated 17 pilgrims with heat stroke on their way to Mecca. More | Follow @MarkHFierce

 @DamianFierce: Barack Obama has no interest in a delay on the 2.3% medical device tax. News | Follow @DamianFierce

> Insulet won FDA 510(k) clearance for its next-generation OmniPod insulin pump. Release

> SQI Diagnostics lost $6.3 million in its fiscal year ending Sept. 30, 2012, an improvement over the $10.7 million net loss reported in fiscal 2011. Release

> Researchers at Rice University and Texas Children's Hospital are successfully using bioscaffolding seeded with living cardiac cells to heal the hearts of infants suffering from birth defects. Release

> With all the problems that metal hip replacements have been causing, Italian researchers are exploring whether wood might make a better--and safer--hip material. Item

> Meridian Bioscience ($VIVO) says it has completed beta trials for two new illumigene diagnostic tests designed to detect gonorrhea and chlamydia DNA from swab and urine samples. Item

> Mindray Medical ($MR), China's largest medical device company, seeking to build its reputation as a major industry player, made its case recently at the Radiological Society of North America conference in Chicago. Story

> A shark's skin has bacterial-resistant properties, and it is the model for a new synthetic coating designed to cover medical devices and hospital equipment. Story

> Zoll Medical Corp. is touting the fact that its intravascular temperature management device successfully treated 17 pilgrims who suffered heat stroke on the annual pilgrimage to Mecca. Release

Biotech News

 @FierceBiotech: Genentech readies for groundbreaking $100M trial of Alzheimer's therapy. News | Follow @FierceBiotech

@JohnCFierce: Cowen out with list of top 10 potential surprises in '13, includes early OK on asfotase; restricting CRPC drugs to metastatic patients. List | Follow @JohnCFierce

@RyanFierce: EMA committee shoots down Sanofi's cholesterol drug mipomersen. News | Follow @RyanMFierce

> Cowen lists top 10 potential surprise catalysts for 2013. Report

> Roche gains blockbuster backing for breast cancer therapy in Europe. Story

Pharma News

@FiercePharma: WSJ: Pfizer animal health IPO could happen next month. Story | Follow @FiercePharma

> Roche looks to earn even more from Perjeta with EU nod. Article

> Lundbeck anti-binge drinking drug gets EU OK. Story